Abcellera Biologics INC. 8-K Filing
Ticker: ABCL · Form: 8-K · Filed: Nov 28, 2025 · CIK: 1703057
| Field | Detail |
|---|---|
| Company | Abcellera Biologics INC. (ABCL) |
| Form Type | 8-K |
| Filed Date | Nov 28, 2025 |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Abcellera Biologics INC. (ticker: ABCL) to the SEC on Nov 28, 2025.
How long is this filing?
Abcellera Biologics INC.'s 8-K filing is 3 pages with approximately 917 words. Estimated reading time is 4 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 917 words · 4 min read · ~3 pages · Grade level 15 · Accepted 2025-11-28 14:20:38
Filing Documents
- abcl-20251124.htm (8-K) — 30KB
- abcl_exhibit161.htm (EX-16.1) — 2KB
- abcl_exhibit161001.jpg (GRAPHIC) — 104KB
- 0001703057-25-000032.txt ( ) — 285KB
- abcl-20251124.xsd (EX-101.SCH) — 2KB
- abcl-20251124_lab.xml (EX-101.LAB) — 20KB
- abcl-20251124_pre.xml (EX-101.PRE) — 12KB
- abcl-20251124_htm.xml (XML) — 3KB
01 Changes in Registrant's Certifying Accountant
Item 4.01 Changes in Registrant's Certifying Accountant (a) Dismissal of Previous Independent Registered Public Accounting Firm On November 24, 2025, the Audit Committee of the Board of Directors (the "Audit Committee") of AbCellera Biologics Inc. (the "Company") approved the dismissal of KPMG LLP ("KPMG") as the Company's independent registered public accounting firm, effective following the completion of KPMG's audit of the Company's consolidated financial statements for the fiscal year ending December 31, 2025, and the filing of the Company's Annual Report on Form 10-K for that fiscal year. The dismissal was not related to any disagreements with KPMG on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure. The audit reports of KPMG on the Company's consolidated financial statements for the fiscal years ended December 31, 2024 and December 31, 2023 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles. During the fiscal years ended December 31, 2024 and December 31, 2023, and the subsequent interim period through the date of this Current Report on Form 8-K, there were no i) disagreements as defined in Item 304(a)(1)(iv) of Regulation S-K between the Company and KPMG on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, and ii) no reportable events as defined in Item 304(a)(1)(v) of Regulation S-K. The Company has provided KPMG with a copy of the disclosures it is making in this Current Report on Form 8-K and has requested that KPMG furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements made herein and, if not, stating the respects in which it does not agree. A copy of such letter provided by KPMG, dated November 28, 2025, is filed as Exhibit 16.1 to this Curren
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 16.1 L etter From KPMG LLP to the Securities Exch a n ge Commission , dated November 2 8 , 2025 . 104 Cover Page Interactive Data File (embedded as Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 28, 2025 ABCELLERA BIOLOGICS INC. By: /s/ Carl L. G. Hansen Carl L. G. Hansen, Ph.D. Chief Executive Officer and Director (Principal Executive Officer)